[Retracted] Analysis of Age and Prevention Strategy on Outcome after Cerebral Venous Thrombosis

Table 1

Baseline characteristics of CVST patients.

	Total (113)	(65)	(48)
Median (IQR 27-48.75)
Female, (%)	63 (55.75%)	41 (63.07%)	22 (44.83%)	0.600
Follow-up period	10 m (6-24 months)
Medical encounter lag time	0.04 d-120 d (average11.11)	12.48	9.26
Median time (IQR)	5.00 (2.00-10.00)	4.50 (2.25-9.75)	5.00 (2.00-14.00)	<0.01
Symptoms and signs, (%)
Headache	98 (86.72%)	61 (93.84%)	37 (77.08%)	0.01
Visual loss	10 (8.85%)	8 (12.31%)	2 (4.17%)	0.18
Papilledema	17 (15.04%)	12 (18.46%)	5 (10.42%)	0.29
Nausea/vomiting	64 (56.63%)	39 (60.00%)	25 (52.08%)	0.44
Stupor or coma	12 (10.62%)	4 (6.15%)	8 (16.67%)	0.12
Motor or sensory deficit	25 (22.12%)	13 (20.00%)	12 (25.00%)	0.64
Seizure	20 (17.70%)	13 (20.00%)	7 (14.6%)	0.61
NIHSS	28 (24.78%)	16 (24.61%)	12 (25.0%)	1.00
Risk factors
None identified	36 (31.86%)	7 (10.77%)	29 (60.42%)	<0.01
Malignancy	3 (2.65%)	2 (3.07%)	1 (2.08%)	1.00
Dural fistula	1 (0.88%)	0 (0.00%)	1 (2.08%)	0.42
Coagulation disorder	14 (12.39%)	8 (12.31%)	6 (12.50%)	1.00
Any systemic prothrombotic disorder	8 (7.08%)	6 (9.23%)	2 (4.17%)	0.46
Polycythemia	2 (1.77%)	1 (1.53%)	1 (2.08%)	1.00
Anemia	8 (7.08%)	8 (12.31%)	0 (0.00%)	0.02
Pregnancy/puerperium	22 (19.47%)	22 (33.84%)	0 (0.00%)	<0.01
Local infection	31 (27.43%)	19 (29.23%)	12 (25.00%)	0.67
Oral contraceptives	3 (2.65%)	3 (4.61%)	0 (0.00%)	0.26
Surgery	8 (7.08%)	8 (12.31%)	0 (0.00%)	0.02
Dehydration	1 (0.88%)	1 (1.53%)	0 (0.0%)	1.00
	94 (83.18%)	55 (84.61%)	39 (81.25%)	0.80
Death by 6 month	3 (2.65%)	1 (1.53%)	2 (4.16%)	0.57
CVST recurrent	10 (8.85%)	4 (6.15%)	6 (12.50%)	0.31

Medical encounter lag time (from symptom onset to first medical encounter).